Information Provided By:
Fly News Breaks for July 8, 2019
Jul 8, 2019 | 07:13 EDT
H.C. Wainwright analyst Douglas Tsao started Protagonist Therapeutics with a Buy rating and $23 price target. While Protagonist's pipeline remains relatively early stage, the Phase 2 data expected later this year for PTG-300 should be an important catalyst for shares since the data may cause investors to assign a much higher valuation to that program, especially as the company should begin work on a second indication, Tsao tells investors in a research note.
News For PTGX From the Last 2 Days
There are no results for your query PTGX